Moreover, CD8B was one of the biomarkers found to be present in more than 10% of the patients who developed an overt autoimmune response after SARS-CoV-2 infection and is one of the four-gene signature panel for a prognostic immune checkpoint blockade in different cancers [107,108]. This evidence concerns the gene CD8B and cancer.